Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 163,078 | 115,694 | 114,888 | 231,731 | 78,229 |
| Marketable Securities | 133,902 | 208,087 | 164,979 | 240,114 | 426,181 |
| Receivables | 82,448 | 69,340 | 151 | N/A | N/A |
| Inventories | 51,678 | 51,520 | 10,372 | N/A | N/A |
| TOTAL | $442,689 | $457,018 | $307,848 | $479,116 | $507,956 |
| Non-Current Assets | |||||
| PPE Net | 131,112 | 109,081 | 114,030 | 105,232 | 100,938 |
| Investments And Advances | 0 | 0 | 0 | 0 | 91,588 |
| Intangibles | 279,324 | 282,398 | 229,258 | 0 | 0 |
| Other Non-Current Assets | 60,045 | 61,929 | 129,215 | 79,634 | 76,851 |
| TOTAL | $470,481 | $453,408 | $472,503 | $184,866 | $269,377 |
| Total Assets | $913,170 | $910,426 | $780,351 | $663,982 | $777,333 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 22,159 | 27,509 | 33,123 | 26,603 | 27,377 |
| Accrued Expenses | 111,156 | 81,936 | 69,406 | 52,295 | 56,766 |
| TOTAL | $138,358 | $122,341 | $110,306 | $91,485 | $89,200 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 1,000 | 1,000 | 1,000 | 1,000 |
| Other Non-Current Liabilities | 44,401 | 44,365 | 67,085 | 71,859 | 65,474 |
| TOTAL | $76,229 | $77,680 | $85,432 | $72,859 | $66,474 |
| Total Liabilities | $214,587 | $200,021 | $195,738 | $164,344 | $155,674 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 411,962 | 327,877 | 279,307 | 224,239 | 157,168 |
| Common Shares | 17 | 13 | 11 | 8 | 7 |
| Retained earnings | -2,775,530 | -2,384,552 | -2,012,375 | -1,568,338 | -1,172,445 |
| Other shareholders' equity | 16,440 | -1,046 | 2,526 | -902 | -601 |
| TOTAL | $698,583 | $710,405 | $584,613 | $499,638 | $621,659 |
| Total Liabilities And Equity | $913,170 | $910,426 | $780,351 | $663,982 | $777,333 |